Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.

Myriad Genetics beat analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $213.3 million, up 11.2% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ EPS estimates and full-year EBITDA guidance exceeding analysts’ expectations.

Is Myriad Genetics a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Myriad Genetics’s revenue to grow 7.8% year on year to $211.9 million, slowing from the 10.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.03 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Myriad Genetics has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3.2% on average.

Looking at Myriad Genetics’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Gilead Sciences delivered year-on-year revenue growth of 6.4%, beating analysts’ expectations by 6.3%, and BioMarin Pharmaceutical reported revenues up 15.6%, topping estimates by 4.8%. Gilead Sciences traded up 7.5% following the results while BioMarin Pharmaceutical was also up 4.6%.

Read our full analysis of Gilead Sciences’s results here and BioMarin Pharmaceutical’s results here.

Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the therapeutics stocks have shown solid performance, the group has generally underpeformed, with share prices down 5.7% on average over the last month. Myriad Genetics is up 10.7% during the same time and is heading into earnings with an average analyst price target of $20.09 (compared to the current share price of $14.35).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.